From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

The association of Agent Orange exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: A population-based study of Vietnam War era veterans

Last Updated: Monday, February 26, 2024

Agent Orange (AO) exposure is linked with an increased risk of multiple myeloma due to the contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Researchers looked at US veterans to determine whether TCDD/AO exposure increases the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) multiple myeloma. Data will also inform progression risk in patients diagnosed with MGUS with occupational TCDD exposure from herbicides and pesticides. 

Journal of Hematology & Oncology
Advertisement
News & Literature Highlights

US Food & Drug Administration

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

Clinica Chimica Acta; International Journal of Clinical Chemistry

Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

New England Journal of Medicine

Teclistamab in multiple myeloma with one to three previous lines of therapy

Annals of Medicine and Surgery

Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study

The Lancet

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

American Journal of Blood Research

Therapy-related B-cell acute lymphoblastic leukemia after treatment for multiple myeloma

Cancer Epidemiology

Occupational pesticide exposure and association of monoclonal gammopathy of undetermined significance in the Western Macroregion of Paraná

Molecular and Cellular Probes

The role of RNA modifications in the pathological mechanisms and therapeutic targeting of multiple myeloma

The FEBS Journal

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

Transplantation and Cellular Therapy

Trial in progress: QUINTESSENTIAL-2—a phase 3 Study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Advertisement
Advertisement